Danaparoid sodium
As of the edition of 20 October 2026, Danaparoid sodium is a drug: marketed, first approved in 1995 (CA); acts on SERPINC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Unknown
- Brand name
- Orgaran
- First approved
- 31 December 1995 (CA)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Aspen; 3 holders in all
- Registered trials
- 2, 1 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SERPINC1 | Antithrombin-III | P01008 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 2 |